Temas de la conferencia
From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.
Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases.
La Sociedad Científica
Hanson Wade
Observaciones
Speakers: Kirby Swatek, Principal Investigator, University of Dundee, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, David Duda, Senior Scientist, Johnson and Johnson and more.
Información e inscripción:
https://go.evvnt.com/1450513-2?pid=4832
Mr. Alex Domingo
CategoríasSalud Pública, Servicios de salud
